Table 2.
Clinical data of patients with BVMD.
| Patient Number | Gender | Age (years) | Phenotype | Stages | Therapies | VA (first visit) | VA (after therapies) | |||
|---|---|---|---|---|---|---|---|---|---|---|
| OD | OS | OD | OS | OD | OS | |||||
| 1 | Male | 30 | BVMD | vitelliform | vitelliform | - | 0.8 | 0.12 | - | - |
|
| ||||||||||
| 2 | Female | 34 | BVMD | vitelliform | vitelliruptive | - | defect | defect | - | - |
|
| ||||||||||
| 3 | Male | 8 | BVMD with OS CNV | vitelliruptive | atrophic/cicatricial | OS IVB∗1 | 0.6 | 0.07 | 0.6 | 0.1 |
|
| ||||||||||
| 4 | Male | 20 | BVMD | vitelliruptive | pseudohypopyon | - | defect | defect | - | - |
|
| ||||||||||
| 6 | Male | 25 | BVMD with OD CNV | atrophic/cicatricial | vitelliruptive | OD IVB∗3/IVC ∗1/IVR∗1 OS IVC∗1 |
0.25 | 0.8 | 1.0 | 1.0 |
|
| ||||||||||
| 8 | Female | 49 | BVMD | vitelliruptive | vitelliruptive | OU PDT∗1 | 0.5 | 0.5 | 0.4 | 0.4 |
|
| ||||||||||
| 9 | Female | 30 | BVMD | vitelliruptive | vitelliruptive | - | 1.0 | 1.2 | - | - |
|
| ||||||||||
| 10 | Male | 38 | BVMD | pseudohypopyon | vitelliruptive | - | 0.25 | 0.25 | - | - |
|
| ||||||||||
| 12 | Male | 4 | BVMD with OD fundus hemorrhage | atrophic/ cicatricial |
vitelliform | - | 0.075 | 0.4 | - | - |
BVMD: best vitelliform macular dystrophy. VA: visual acuity. OD: oculus dexter, right eye. OS: oculus sinister, left eye. OU: oculus uterque, binoculus. CNV: choroidal neovascularization. IVB: intravitreal injection of bevacizumab. IVC: intravitreal injection of conbercept. IVR: intravitreal injection of ranibizumab. PDT: photodynamic therapy. Asterisks mean times of therapy. Blank sections mean no data available.